Bubendorf/Basel, August 29, 2014 – Bachem Group (SIX: BANB) significantly improved its performance in terms of sales and profit during the first half of 2014 and confirmed its continuous growth expectations. Bachem increased its sales to 86.7 million CHF (+8.2% in local currency). Operating income advanced 28.8% to 16.4 million CHF. That figure includes a gain of 2.0 million CHF on the divestment of its immunology product line. The EBIT and net income margins rose to 18.9% and 14.3%, respectively, partly because of the non-recurring divestment gain. The equity ratio is at a solid level of 78.5%. Management is confident the targeted increases in full-year sales and net income will be achieved.